| Lacy Marie Crum, | |
|
227 Falcon Dr # 104, Mt Sterling, KY 40353-9792 | |
| (859) 497-5160 | |
| (859) 497-5166 |
| Full Name | Lacy Marie Crum |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 227 Falcon Dr # 104, Mt Sterling, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174127781 | NPI | - | NPPES |
| 7100771230 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | PA2799 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lacy Marie Crum, Po Box 936, London, KY 40743-0936 Ph: (859) 497-5160 | Lacy Marie Crum, 227 Falcon Dr # 104, Mt Sterling, KY 40353-9792 Ph: (859) 497-5160 |
News Archive
Effective management of neonatal abstinence syndrome- withdrawal symptoms occurring in infants exposed to opioids in utero - requires a coordinated "cascade of care" from prevention through long-term follow-up, reports a study in Advances in Neonatal Care, official journal of the National Association of Neonatal Nurses. The journal is published in the Lippincott portfolio by Wolters Kluwer.
An international team of scientists, led by researchers from the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore and National Cancer Centre of Singapore, has identified hundreds of novel genes that are mutated in stomach cancer, the second-most lethal cancer worldwide.
BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company's second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
Obesity levels are at an all-time high among men, women, and children in the United States. The need for good nutrition and regular exercise is paramount for maintaining proper health and for keeping those extra pounds at bay, especially for women.
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib, a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer.
› Verified 7 days ago
Makenzie Kinder, MSPAS, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 401 Commerce Cir, Mt Sterling, KY 40353 Phone: 859-498-5243 Fax: 859-498-5396 | |
Monika Rae Potter, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 227 Falcon Dr Ste 104, Mt Sterling, KY 40353 Phone: 859-497-5459 Fax: 859-497-5470 | |
Mrs. Taylor R Elam, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 624 Maysville Rd, Mt Sterling, KY 40353 Phone: 859-497-4144 Fax: 859-498-4137 | |
Ashley M Ward, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 401 Commerce Cir, Mt Sterling, KY 40353 Phone: 859-498-5243 Fax: 859-498-5396 | |
Mrs. Fallon Smith Hall, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 148 Skyview Dr, Mt Sterling, KY 40353 Phone: 859-499-0717 Fax: 859-499-0926 | |
Mrs. Elizabeth Majorie Snedeker, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 401 Commerce Cir, Mt Sterling, KY 40353 Phone: 859-498-5243 Fax: 859-498-5396 |